SAN DIEGO, March 4, 2014 /PRNewswire/ -- GenomeDx Biosciences announced that it will present today at the 34th Annual Cowen and Company Healthcare Conference at 4:30 p.m. ET in Boston, Massachusetts. Doug Dolginow, M.D., CEO of GenomeDx, will provide a progress update on the commercialization of its Decipher® test and an overview of the Company's product pipeline in urology.
The Decipher Prostate Cancer Classifier is a genomic test that directly measures the biological risk of metastatic prostate cancer. By assessing the activity of multiple genomic markers associated with metastatic disease, Decipher provides information about the aggressiveness of a patient's tumor – information distinct from that provided by PSA and other clinical tools. Through an extensive program of clinical studies, Decipher continues to demonstrate its ability to more accurately distinguish metastatic disease and impact treatment decisions for men with prostate cancer.
Decipher is commercially available to eligible US patients through their physicians and as a part of GenomeDx's ongoing program of clinical studies.
To learn more about the Decipher test, please visit www.deciphertest.com.
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that impact treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. GenomeDx has developed the Decipher Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. www.genomedx.com
SOURCE GenomeDx Biosciences